Whole exome sequencing Gene package Neurodegeneration version 3,

Transcription

1 Whole Exome Sequencing Gene package Neurodegeneration, version 3, Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA MEM algorithm (reference: bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. Additionally, MPLA analysis was performed for APP (SALSA P170 APP; MRC Holland) and several (fragments of) Parkinson genes (SALSA P051/P052 Parkinson probemix). For ATN1 and C9orf72 a repeat expansion test was performed. PRNP was also tested by Sanger sequencing. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including phenotype ID(s) AAAS Achalasia addisonianism alacrimia syndrome, ABCD1 Adrenoleukodystrophy, Adrenomyeloneuropathy, adult, ALS2 Amyotrophic lateral sclerosis 2, juvenile, Primary lateral sclerosis, juvenile, Spastic paralysis, infantile onset ascending, ANG Amyotrophic lateral sclerosis 9, ANXA11 Amytrophic lateral sclerosis 23, APP Alzheimer disease 1, familial, Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants, ARHGEF28 No phenotype ATP13A2 Kufor Rakeb syndrome, Spastic paraplegia 78, autosomal recessive, ATP1A3 Alternating hemiplegia of childhood 2, CAPOS syndrome, Dystonia 12, ATP6AP2 Mental retardation, X linked, syndromic, Hedera type, ?Parkinsonism with spasticity, X linked,

2 Phenotype description including phenotype ID(s) AUH 3 methylglutaconic aciduria, type I, C19orf12 Neurodegeneration with brain iron accumulation 4, ?Spastic paraplegia 43, autosomal recessive, C9orf72 Frontotemporal dementia and/or amyotrophic lateral sclerosis 1, CAV1?Lipodystrophy, congenital generalized, type 3, ?Partial lipodystrophy, congenital cataracts, and neurodegeneration syndrome, Pulmonary hypertension, primary, 3, CBS Homocystinuria, B6 responsive and nonresponsive types, Thrombosis, hyperhomocysteinemic, CHCHD10 Frontotemporal dementia and/or amyotrophic lateral sclerosis 2, ?Myopathy, isolated mitochondrial, autosomal dominant, Spinal muscular atrophy, Jokela type, CHCHD2 Parkinson disease 22, autosomal dominant, CHMP2B Amyotrophic lateral sclerosis 17, Dementia, familial, nonspecific, CISD2 Wolfram syndrome 2, CLCN2 {Epilepsy, idiopathic generalized, susceptibility to, 11}, {Epilepsy, juvenile absence, susceptibility to, 2}, {Epilepsy, juvenile myoclonic, susceptibility to, 8}, Leukoencephalopathy with ataxia, CLN3 Ceroid lipofuscinosis, neuronal, 3, CLN5 Ceroid lipofuscinosis, neuronal, 5, CLN6 Ceroid lipofuscinosis, neuronal, 6, Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, CLN8 Ceroid lipofuscinosis, neuronal, 8, Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, COASY Neurodegeneration with brain iron accumulation 6, COL4A1 Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps, Brain small vessel disease with or without ocular anomalies, {Hemorrhage, intracerebral, susceptibility to}, Porencephaly 1, ?Retinal arteries, tortuosity of, Schizencephaly, COL4A2 {Hemorrhage, intracerebral, susceptibility to}, Porencephaly 2, CP Cerebellar ataxia, Hemosiderosis, systemic, due to aceruloplasminemia, [Hypoceruloplasminemia, hereditary],

3 Phenotype description including phenotype ID(s) CRAT?Neurodegeneration with brain iron accumulation 8, CSF1R Leukoencephalopathy, diffuse hereditary, with spheroids, CST3 Cerebral amyloid angiopathy, {Macular degeneration, age related, 11}, CTSA Galactosialidosis, CTSD Ceroid lipofuscinosis, neuronal, 10, CTSF Ceroid lipofuscinosis, neuronal, 13, Kufs type, CYP27A1 Cerebrotendinous xanthomatosis, DARS2 Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, DCAF17 Woodhouse Sakati syndrome, DCTN1 {Amyotrophic lateral sclerosis, susceptibility to}, Neuropathy, distal hereditary motor, type VIIB, Perry syndrome, DNAJC13 No phenotype DNAJC5 Ceroid lipofuscinosis, neuronal, 4, Parry type, DNAJC6 Parkinson disease 19a, juvenile onset, Parkinson disease 19b, early onset, DNMT1 Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, Neuropathy, hereditary sensory, type IE, EIF4G1 {Parkinson disease 18}, ERBB4 Amyotrophic lateral sclerosis 19, FA2H Spastic paraplegia 35, autosomal recessive, FBXO7 Parkinson disease 15, autosomal recessive, FIG4 Amyotrophic lateral sclerosis 11, Charcot Marie Tooth disease, type 4J, ?Polymicrogyria, bilateral temporooccipital, Yunis Varon syndrome, FOLR1 Neurodegeneration due to cerebral folate transport deficiency, FTL Hyperferritinemia cataract syndrome, L ferritin deficiency, dominant and recessive, Neurodegeneration with brain iron accumulation 3, FUS Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, Essential tremor, hereditary, 4, GBE1 Glycogen storage disease IV, Polyglucosan body disease, adult form, GFAP Alexander disease, GIGYF2 {Parkinson disease 11},

4 Phenotype description including phenotype ID(s) GLA Fabry disease, Fabry disease, cardiac variant, GRN Aphasia, primary progressive, Ceroid lipofuscinosis, neuronal, 11, Frontotemporal lobar degeneration with ubiquitin positive inclusions, GSN Amyloidosis, Finnish type, HEXA GM2 gangliosidosis, several forms, [Hex A pseudodeficiency], Tay Sachs disease, HEXB Sandhoff disease, infantile, juvenile, and adult forms, HNRNPA1 Amyotrophic lateral sclerosis 20, ?Inclusion body myopathy with early onset Paget disease without frontotemporal dementia 3, HNRNPA2B1?Inclusion body myopathy with early onset Paget disease with or without frontotemporal dementia 2, HTRA1 CARASIL syndrome, Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2, {Macular degeneration, age related, 7}, {Macular degeneration, age related, neovascular type}, HTRA2 3 methylglutaconic aciduria, type VIII, {Parkinson disease 13}, ITM2B Dementia, familial British, Dementia, familial Danish, ?Retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities, KCTD7 Epilepsy, progressive myoclonic 3, with or without intracellular inclusions, LMNB1 Leukodystrophy, adult onset, autosomal dominant, LRP10 No phenotype LRRK2 {Parkinson disease 8}, MAPT Dementia, frontotemporal, with or without parkinsonism, {Parkinson disease, susceptibility to}, Pick disease, Supranuclear palsy, progressive, Supranuclear palsy, progressive atypical, MATR3 Amyotrophic lateral sclerosis 21, MED20 No phenotype MFSD8 Ceroid lipofuscinosis, neuronal, 7, Macular dystrophy with central cone involvement, MMACHC Methylmalonic aciduria and homocystinuria, cblc type,

5 Phenotype description including phenotype ID(s) NOTCH3 Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy 1, Lateral meningocele syndrome, ?Myofibromatosis, infantile 2, NPC1 Niemann Pick disease, type C1, Niemann Pick disease, type D, NPC2 Niemann pick disease, type C2, OPTN Amyotrophic lateral sclerosis 12, Glaucoma 1, open angle, E, {Glaucoma, normal tension, susceptibility to}, PAH [Hyperphenylalaninemia, non PKU mild], Phenylketonuria, PANK2 HARP syndrome, Neurodegeneration with brain iron accumulation 1, PARK7 Parkinson disease 7, autosomal recessive early onset, PDGFB Basal ganglia calcification, idiopathic, 5, Dermatofibrosarcoma protuberans, Meningioma, SIS related, PDGFRB Basal ganglia calcification, idiopathic, 4, Kosaki overgrowth syndrome, Myeloproliferative disorder with eosinophilia, Myofibromatosis, infantile, 1, Premature aging syndrome, Penttinen type, PFN1 Amyotrophic lateral sclerosis 18, PINK1 Parkinson disease 6, early onset, PLA2G6 Infantile neuroaxonal dystrophy 1, Neurodegeneration with brain iron accumulation 2B, Parkinson disease 14, autosomal recessive, POLG Mitochondrial DNA depletion syndrome 4A (Alpers type), Mitochondrial DNA depletion syndrome 4B (MNGIE type), Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), Progressive external ophthalmoplegia, autosomal dominant 1, Progressive external ophthalmoplegia, autosomal recessive 1, PPT1 Ceroid lipofuscinosis, neuronal, 1, PRKAR1B No phenotype PRKN Adenocarcinoma of lung, somatic, Adenocarcinoma, ovarian, somatic, {Leprosy, susceptibility to}, Parkinson disease, juvenile, type 2,

6 Phenotype description including phenotype ID(s) PRKRA Dystonia 16, PRNP Cerebral amyloid angiopathy, PRNP related, Creutzfeldt Jakob disease, Gerstmann Straussler disease, Huntington disease like 1, Insomnia, fatal familial, {Kuru, susceptibility to}, Prion disease with protracted course, PSEN1?Acne inversa, familial, 3, Alzheimer disease, type 3, Alzheimer disease, type 3, with spastic paraparesis and apraxia, Alzheimer disease, type 3, with spastic paraparesis and unusual plaques, Cardiomyopathy, dilated, 1U, Dementia, frontotemporal, Pick disease, PSEN2 Alzheimer disease 4, Cardiomyopathy, dilated, 1V, PSENEN Acne inversa, familial, 2, with or without Dowling Degos disease, PTRHD1 No phenotype QARS Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, SERPINI1 Encephalopathy, familial, with neuroserpin inclusion bodies, SETX Amyotrophic lateral sclerosis 4, juvenile, Spinocerebellar ataxia, autosomal recessive 1, SIGMAR1?Amyotrophic lateral sclerosis 16, juvenile, ?Spinal muscular atrophy, distal, autosomal recessive, 2, SLC17A5 Salla disease, Sialic acid storage disorder, infantile, SLC20A2 Basal ganglia calcification, idiopathic, 1, SLC33A1 Congenital cataracts, hearing loss, and neurodegeneration, Spastic paraplegia 42, autosomal dominant, SLC39A14 Hypermanganesemia with dystonia 2, ?Hyperostosis cranalis interna, SLC6A3 {Nicotine dependence, protection against}, Parkinsonism dystonia, infantile, SMPD1 Niemann Pick disease, type A, Niemann Pick disease, type B,

7 Phenotype description including phenotype ID(s) SNCA Dementia, Lewy body, Parkinson disease 1, Parkinson disease 4, SNCB Dementia, Lewy body, SOD1 Amyotrophic lateral sclerosis 1, SORL1 No phenotype SPG11 Amyotrophic lateral sclerosis 5, juvenile, Charcot Marie Tooth disease, axonal, type 2X, Spastic paraplegia 11, autosomal recessive, SPR Dystonia, dopa responsive, due to sepiapterin reductase deficiency, SQSTM1 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3, Myopathy, distal, with rimmed vacuoles, Neurodegeneration with ataxia, dystonia, and gaze palsy, childhood onset, Paget disease of bone 3, SYNJ1 Epileptic encephalopathy, early infantile, 53, Parkinson disease 20, early onset, TAF1 Dystonia Parkinsonism, X linked, Mental retardation, X linked, syndromic 33, TANGO2 Metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration, TARDBP Amyotrophic lateral sclerosis 10, with or without FTD, Frontotemporal lobar degeneration, TARDBP related, TBK1 {Encephalopathy, acute, infection induced (herpes specific), susceptibility to, 8}, Frontotemporal dementia and/or amyotrophic lateral sclerosis 4, TH Segawa syndrome, recessive, TPP1 Ceroid lipofuscinosis, neuronal, 2, Spinocerebellar ataxia, autosomal recessive 7, TREM2 Nasu Hakola disease, TREX1 Aicardi Goutieres syndrome 1, dominant and recessive, Chilblain lupus, {Systemic lupus erythematosus, susceptibility to}, Vasculopathy, retinal, with cerebral leukodystrophy, TTR Amyloidosis, hereditary, transthyretin related, Carpal tunnel syndrome, familial, [Dystransthyretinemic hyperthyroxinemia], TUBA4A Amyotrophic lateral sclerosis 22 with or without frontotemporal dementia, TYMP Mitochondrial DNA depletion syndrome 1 (MNGIE type), TYROBP Nasu Hakola disease,

8 Phenotype description including phenotype ID(s) UBQLN2 Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, UCHL1 {?Parkinson disease 5, susceptibility to}, Spastic paraplegia 79, autosomal recessive, VAPB Amyotrophic lateral sclerosis 8, Spinal muscular atrophy, late onset, Finkel type, VCP Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia, Charcot Marie Tooth disease, type 2Y, Inclusion body myopathy with early onset Paget disease and frontotemporal dementia 1, VPS13C Parkinson disease 23, autosomal recessive, early onset, VPS35 {Parkinson disease 17}, WDR45 Neurodegeneration with brain iron accumulation 5, XPR1 Basal ganglia calcification, idiopathic, 6, Gene symbols according HGCN release used: "No phenotypes" indicates a gene without a current association phenotypes between "[ ]", indicate "nondiseases," mainly genetic variations that lead to apparently abnormal laboratory test values phenotypes between "{}", indicate risk factors phenotypes with a question mark, "?", before the disease name indicates an unconfirmed or possibly spurious mapping The statistics above are based on a set of 95 samples Median depth is the median of the mean sequence depth over the protein coding exons (±10bp flanking introns) of the longest transcript % Covered 10x describes the percentage of a gene s coding sequence (±10bp flanking introns) that is covered at least 10x % Covered 20x describes the percentage of a gene s coding sequence (±10bp flanking introns) that is covered at least 20x % Covered 30x describes the percentage of a gene s coding sequence (±10bp flanking introns) that is covered at least 30x